Akebia Therapeutics, Inc. - Common Stock (AKBA)
2.1000
-0.9900 (-32.04%)
NASDAQ · Last Trade: Oct 29th, 4:45 PM EDT
Detailed Quote
| Previous Close | 3.090 |
|---|---|
| Open | 2.160 |
| Bid | 2.120 |
| Ask | 2.140 |
| Day's Range | 2.080 - 2.560 |
| 52 Week Range | 1.520 - 4.079 |
| Volume | 25,578,011 |
| Market Cap | 366.53M |
| PE Ratio (TTM) | -11.67 |
| EPS (TTM) | -0.2 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 2,737,586 |
Chart
About Akebia Therapeutics, Inc. - Common Stock (AKBA)
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease. The company is primarily engaged in addressing unmet medical needs in anemia caused by chronic kidney disease, aiming to enhance patient outcomes through its proprietary treatments and drug candidates. Akebia's research and development efforts are centered around creating therapies that improve the management of renal diseases by promoting better health and quality of life for patients suffering from kidney-related conditions. Read More
News & Press Releases
Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding Vafseo's label.
Via Benzinga · October 29, 2025
Via Benzinga · October 29, 2025
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansionstocktwits.com
Via Stocktwits · October 29, 2025
Via Benzinga · October 29, 2025
Via Benzinga · October 29, 2025
Via Benzinga · October 29, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · October 28, 2025
Via Benzinga · October 28, 2025
Via Benzinga · May 8, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · March 20, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Via Benzinga · March 20, 2025
Via Benzinga · March 20, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · March 19, 2025
